H. Muss

发表

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

D. Berry, E. Winer, E. Perez, 2006, JAMA.

Diagnosis and Treatment of Breast Cancer in the Elderly

H. Muss, C. Holmes, 2003, CA: a cancer journal for clinicians.

Predicting participation in meaningful activity for older adults with cancer

H. Muss, M. Pergolotti, M. Cutchin, 2015, Quality of Life Research.

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

Larry Norton, Donald A Berry, Edith A Perez, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Barbara L. Smith, Robert Livingston, Richard L Schilsky, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article.

Murielle Mauer, Supriya G Mohile, Giuseppe Curigliano, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

D A Berry, D. Berry, L. Norton, 1998, Journal of the National Cancer Institute.

Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.

H. Cohen, M. Theodoulou, A. Wolff, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Discrepancy between preference and actual adjuvant therapy for breast cancer.

Takamaru Ashikaga, T. Ashikaga, H. Muss, 2010, Clinical breast cancer.

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Richard L Schilsky, Larry Norton, James N Ingle, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Commentary (Kimmick/Muss): The Effect of Tamoxifen on the Endometrium

G. Kimmick, H. Muss, 1995 .

American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting.

Thomas J. Smith, Thomas J Smith, Eva Grunfeld, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A question of duration: do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy?

H. Muss, S. Burdette-Radoux, 2009, Clinical breast cancer.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

Donald A. Berry, Eric P. Winer, Larry Norton, 2006 .

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

Robert B Livingston, Dongsheng Tu, Jeffrey S Abrams, 2005, Journal of the National Cancer Institute.

Systemic therapy for older women with breast cancer.

G. Kimmick, H. Muss, Gretchen Kimmick, 2001, Oncology.

Tamoxifen in Postmenopausal Women

G. Kimmick, H. Muss, E. Robinson, 1996, Drugs & aging.

Breast and ovarian cancer in the older woman.

G. Kimmick, H. Muss, W. Tew, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclin D‐1, Interleukin‐6, HER‐2/neu, Transforming Growth Factor Receptor‐II and Prediction of Relapse in Women with Early Stage, Hormone Receptor‐Positive Breast Cancer Treated with Tamoxifen

D. Weaver, J. Bunn, J. Koh, 2007, The breast journal.

Clinical cardiotoxicity of esorubicin (4′-deoxydoxorubicin,DxDx): Prospective studies with serial gated heart scans and reports of selected cases

R. Schilsky, L. Norton, Mark R. Green, 1990, Investigational new drugs.

Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.

J. Ingle, P. Goss, W. Parulekar, 2008, Journal of the National Cancer Institute.

Pharmacokinetics of vincristine sulfate in adult cancer patients.

C. Spurr, H. Muss, M. Cooper, 1981, Cancer research.

Biological and Hormonal Therapies of Cancer

K. Foon, H. Muss, 1998, Cancer Treatment and Research.

Biological, clinical, and psychosocial correlates at the interface of cancer and aging research.

H. Cohen, E. Trimble, R. Schilsky, 2012, Journal of the National Cancer Institute.

Activities, function, and health-related quality of life (HRQOL) of older adults with cancer.

B. Reeve, A. Deal, A. Bryant, 2017, Journal of geriatric oncology.

Geriatric Assessment of Older Adults With Cancer During Unplanned Hospitalizations: An Opportunity in Disguise.

A. Deal, A. Bryant, H. Muss, 2015, The oncologist.

InCHIANTI study Sarcopenic obesity and inflammation in the

H. Cohen, S. Bandinelli, L. Ferrucci, 2015 .

Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.

D. Berry, E. Winer, D. Lake, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors

Timothy W. Smith, H. Muss, C. Melvin, 2014, Journal of Cancer Survivorship.

Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice?

E. Winer, C. Hudis, M. Citron, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Coming of age: breast cancer in seniors.

H. Muss, 2010, The oncologist.

Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.

E. Perez, M. Piccart, S. Martino, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.

D. Berry, E. Winer, C. Hudis, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.

E. Perez, M. Piccart, S. Martino, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy in the elderly: whom to treat, what regimen?

H. Muss, S. Burdette-Radoux, 2006, The oncologist.

Frailty and health-related quality of life in older women with breast cancer

B. Reeve, A. Deal, H. Muss, 2018, Supportive Care in Cancer.

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.

H. Cohen, E. Winer, J. Foster, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incorporating biomarkers into cancer and aging research.

H. Cohen, H. Muss, J. Hubbard, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimizing the use of anthracyclines in the adjuvant treatment of early-stage breast cancer.

H. Muss, S. Burdette-Radoux, 2003, Clinical Breast Cancer.

Inflammatory markers and overall survival in older adults with cancer.

A. Deal, J. Lund, H. Muss, 2019, Journal of geriatric oncology.

Improvement of long-term survival in extensive small-cell lung cancer.

L. Case, H. Muss, P. Zekan, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Participation in clinical treatment trials: Factors affecting participation for women with breast cancer

E. Paskett, L. Case, H. Muss, 1996 .

Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.

H. Linden, J. Ingle, J. St. Louis, 2014, The Lancet. Oncology.

Integrating Patient-Reported Outcome Measures into Routine Cancer Care: Cancer Patients’ and Clinicians’ Perceptions of Acceptability and Value

Ronald C. Chen, W. Wood, B. Reeve, 2015, EGEMS.

Chemotherapy versus chemoimmunotherapy in advanced adenocarcinoma of the colon and rectum. A prospective randomized study

C. Spurr, H. Muss, F. Richards, 1979, Cancer.

From medical oncologist to geriatric oncologist—Worth the trip

H. Muss, 2011 .

Cancer Chemotherapy in Older Adults

G. Kimmick, H. Muss, L. Balducci, 1997, Drugs & aging.

The use of psychological supportive care services and psychotropic drugs in patients with early-stage breast cancer: a comparison between two institutions on two continents

L. Livi, L. Marks, A. Deal, 2017, Medical Oncology.

New Hormones for Advanced Breast Cancer.

H. Muss, 1999, Cancer control : journal of the Moffitt Cancer Center.

Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association.

H. Muss, B. Powell, M. Cooper, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association.

C. Spurr, L. Case, H. Muss, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.

L. Case, H. Muss, B. Loggie, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.

D. Berry, L. Norton, L. Dressler, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy

A. Deal, H. Muss, G. Williams, 2016, Clinical Cancer Research.

The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).

H. Cohen, A. Jatoi, J. Ligibel, 2017, Journal of geriatric oncology.

A. Deal, H. Muss, K. Nyrop, 2020, Nutrition and cancer.

Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?

L. Carey, A. Deal, H. Muss, 2017, Breast Cancer Research and Treatment.

Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review

L. Carey, A. Deal, H. Muss, 2017, Breast Cancer Research and Treatment.

Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?

H. Muss, S. Shachar, G. Williams, 2016, Breast Cancer Research and Treatment.

Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.

Thomas J. Smith, L. Esserman, M. Somerfield, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.

D. Berry, E. Winer, C. Hudis, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.

D. Berry, L. Norton, D. Cowan, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential Medication-Related Problems in Older Breast, Colon, and Lung Cancer Patients in the United States

T. Stürmer, J. Lund, V. Pate, 2017, Cancer Epidemiology, Biomarkers & Prevention.

Patient‐reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer

L. Carey, E. Basch, W. Wood, 2020, Cancer.

Breast cancer: factors associated with stage at diagnosis in black and white women. Black/White Cancer Survival Study Group.

C. Redmond, B. Edwards, M. Forman, 1993, Journal of the National Cancer Institute.

Data Linkage to Improve Geriatric Oncology Research: A Feasibility Study

A. Deal, J. Lund, H. Muss, 2017, The oncologist.

Cancer Treatment as an Accelerated Aging Process: Assessment, Biomarkers, and Interventions.

L. Jones, H. Muss, A. Hurria, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Prevalence and clinical correlates of cognitive impairment in adults with plasma cell disorders.

W. Wood, S. Tuchman, A. Deal, 2022, Journal of geriatric oncology.

Breast Cancer in Women Older Than 80 Years.

H. Muss, A. Hurria, S. Shachar, 2016, Journal of oncology practice.

Clinical research in the older cancer patient.

H. Cohen, H. Muss, S. Lichtman, 2000, Hematology/oncology clinics of North America.

Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology.

H. Cohen, J. Buckner, J. Mandelblatt, 2020, Journal of geriatric oncology.

Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials

J. Crawford, B. Peterson, N. Bartlett, 2002, Cancer.

Barriers to clinical trial participation by older women with breast cancer.

H. Cohen, B. Peterson, N. Bartlett, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Barriers t o C linical T rial P articipation b y O lder W omen W ith Breast C ancer

H. Cohen, B. Peterson, N. Bartlett, 2003 .

Skeletal muscle measures and physical function in older adults with cancer: sarcopenia or myopenia?

A. Deal, H. Muss, H. Sanoff, 2017, Oncotarget.

Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG

D. Berry, E. Winer, E. Perez, 2005 .

Geriatric assessment in surgical oncology: a systematic review.

Karen E Crowell, M. Nielsen, Angela B Smith, 2015, The Journal of surgical research.

Symptom management in metastatic breast cancer.

H. Muss, W. Irvin, D. Mayer, 2011, The oncologist.

Breast cancer in the elderly

A. Goldhirsch, M. Aapro, M. Baum, 2010 .

Advanced epidermoid lung cancer. Prolonged survival after chemotherapy

C. Spurr, H. Muss, M. Cooper, 1980, Cancer.

Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622).

H. Cohen, M. Edelman, J. Feliciano, 2018, Journal of geriatric oncology.

Do Older Patients with Metastatic Non-Small Cell Lung Cancer Also Benefit from First-Line Platinum-Based Doublet Chemotherapy?: Observations from a Pooled Analysis of 730 Prospectively-Treated Patients (Alliance Study

H. Cohen, M. Edelman, J. Feliciano, 2018 .

Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis.

H. Muss, Y. Takamatsu, K. Tamura, 2015, Cancer treatment reviews.

Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806

D. Berry, E. Winer, C. Hudis, 2006, Breast Cancer Research and Treatment.

Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance.

A. Deal, H. Muss, S. Choi, 2018, Journal of oncology practice.

Anthracycline vs Nonanthracycline Adjuvant Therapy for Breast Cancer

H. Muss, 2017 .

Nab‐paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum‐based doublet chemotherapy

M. Socinski, T. Stinchcombe, Carrie Lee, 2020, Cancer.

Combination chemotherapy of advanced non‐oat cell carcinoma of the lung

C. Spurr, H. Muss, M. Cooper, 1979, Cancer.

Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin Versus doxorubicin and cyclophosphamide (a phase III trial of the gynecologic oncology group)

P. Disaia, E. Yordan, H. Muss, 1985, Cancer.

Bioelectrical Impedance Analysis for the Assessment of Sarcopenia in Patients with Cancer: A Systematic Review.

C. Battaglini, H. Muss, G. Williams, 2019, The oncologist.

Multiple primary bronchogenic carcinomas of the lung.

H. Muss, R. Choplin, S. Bower, 1983, AJR. American journal of roentgenology.

Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high-dose therapy.

G. Evans, J. Brockschmidt, H. Muss, 1990, Seminars in oncology.

Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.

J. Wanders, F. Cardoso, J. O’Shaughnessy, 2014, The oncologist.

Improving the quality of survivorship for older adults with cancer

S. Studenski, H. Allore, S. Inouye, 2016, Cancer.

Breast Cancer Chemoprevention in an Integrated Health Care Setting.

T. Stürmer, H. Muss, L. Kushi, 2017, JCO clinical cancer informatics.

Is "Geriatric" Assessment Just for Older Patients?

W. Wood, H. Muss, S. Choi, 2019, The oncologist.

Second primary bronchogenic carcinomas after small cell carcinoma. Report of two cases and review of the literature.

H. Muss, B. Powell, E. Kawamoto, 1984, The American journal of medicine.

Initiation of Aspirin Therapy Modulates Angiogenic Protein Levels in Women with Breast Cancer Receiving Tamoxifen Therapy

J. Skelly, H. Muss, C. Holmes, 2013, Clinical and translational science.

Older‐Patient‐Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715)

H. Cohen, M. Citron, L. Carey, 2019, The oncologist.

The Cancer and Leukemia Group B Cancer in the Elderly Committee: Addressing a Major Cancer Need

H. Cohen, H. Muss, 2006, Clinical Cancer Research.

Older age--not a barrier to cancer treatment.

H. Muss, 2001, The New England journal of medicine.

Quality of life changes during the pre‐ to postdiagnosis period and treatment‐related recovery time in older women with breast cancer

B. Reeve, H. Muss, S. Wheeler, 2014, Cancer.

Endocrine therapy use among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors.

Timothy W. Smith, H. Muss, C. Melvin, 2012 .

Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane–Based Chemotherapy for Early-Stage Breast Cancer

A. Deal, H. Muss, S. Choi, 2017, Clinical Cancer Research.

Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al.

Barbara L. Smith, D. Berry, E. Winer, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of ED and hospital services for patients with acute leukemia after induction therapy: one year follow-up.

W. Wood, A. Deal, A. Bryant, 2015, Leukemia research.

Histological characteristics of breast carcinoma in blacks and whites.

C. Redmond, R. Kurman, J. Eley, 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Multidisciplinary Management of Breast Cancer During Pregnancy.

C. Anders, H. Muss, K. McGuire, 2017, The oncologist.

Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse.

B. Kennedy, N. Sharpless, S. Melov, 2017, Cancer discovery.

Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase.

C. Spurr, H. Muss, M. Cooper, 1984, Blood.

Secondary malignancies of the penis and epididymis: a case report and review of the literature.

H. Muss, B. Powell, H. Muss, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy vs. chemoimmunotherapy with methanol extraction residue of bacillus calmette‐guerin (MER) in advanced breast cancer: A randomized trial by the piedmont oncology association

C. Spurr, H. Muss, M. Cooper, 1981, Cancer.

Perceptions of Follow‐Up Care in Women with Breast Cancer

P. Robertson, G. Tell, L. Case, 1991, American journal of clinical oncology.

A Phase II Trial of 5‐Fluorouracil and High‐Dose Leucovorin in Recurrent Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study

H. Muss, J. Blessing, K. Look, 1995, American journal of clinical oncology.

Vaginal Estrogens and Aromatase Inhibitors: How Safe Is Safe Enough?

H. Muss, K. Reeder-Hayes, 2017, JAMA oncology.

Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).

H. Cohen, E. Winer, C. Hudis, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis.

S. Moschos, H. Muss, S. Shachar, 2016, Cancer treatment reviews.

A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis

H. Muss, Maya Suzuki, T. Nishijima, 2016, Breast Cancer Research and Treatment.

A comparison of treatment outcomes for black patients and white patients with metastatic breast cancer. The piedmont oncology association experience

G. Kimmick, H. Muss, L. Douglas Case, 1991, Cancer.

Adriamycin versus methotrexate in five‐drug combination chemotherapy for advanced breast cancer. A randomized trial

C. Spurr, H. Muss, M. Cooper, 1978, Cancer.

The use of flow cytometry for the prognosis of stage II adjuvant treated breast cancer patients

L. Case, H. Muss, T. Kute, 1990, Cancer.

The role of HER-2 + Topo IIα amplification in predicting benefit from CAF dose escalation-CALGB 8541.

D. Berry, M. Ellis, D. Cowan, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frailty and skeletal muscle in older adults with cancer.

A. Deal, H. Muss, H. Sanoff, 2018, Journal of geriatric oncology.

Adrenal Hormone and Metabolic Biomarker Responses to 30 min of Intermittent Cycling Exercise in Breast Cancer Survivors

R. Mcmurray, A. Deal, A. Hackney, 2016, International Journal of Sports Medicine.

Comprehensive Geriatric Assessment-Guided Therapy Does Improve Outcomes of Older Patients With Advanced Lung Cancer.

S. Mohile, A. Gajra, W. Dale, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to L.K. Mell et al.

H. Cohen, H. Wildiers, M. Mauer, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single agent vincristine by infusion in refractory multiple myeloma.

C. Spurr, L. Case, H. Muss, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ASCO 2020: The Geriatric Assessment comes of Age.

M. Aapro, H. Muss, E. Soto-Pérez-de-Celis, 2020, The oncologist.

The Effects of 16 Weeks of Exercise Training on Neutrophil Functions in Breast Cancer Survivors

B. Jensen, A. Deal, C. Battaglini, 2021, Frontiers in Immunology.

A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer

J. Doroshow, J. Bennett, C. Vogel, 1985, Investigational New Drugs.

Biopsy of breast cancer metastases: patient characteristics and survival

G. Bar-Sela, H. Muss, K. Drumea, 2017, BMC Cancer.

Immunoglobulin D benign monoclonal gammopathy. A case report

H. Muss, D. Buss, M. L. O'connor, 1991, Cancer.

Physical Function, Psychosocial Status, and Symptom Burden Among Adults with Plasma Cell Disorders and Associations with Quality of Life

W. Wood, S. Tuchman, A. Deal, 2022, The oncologist.

Impact of community-based exercise on fatigue in early breast cancer survivors: identifying potential determinants of change

C. Battaglini, H. Muss, Z. Kerr, 2022, Breast Cancer.

Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, p16INK4a

L. Carey, C. Anders, E. Dees, 2020, JNCI cancer spectrum.

Tamoxifen and Aromatase Inhibitors Differentially Affect Vascular Endothelial Growth Factor and Endostatin Levels in Women with Breast Cancer

A. Howard, H. Muss, C. Holmes, 2008, Clinical Cancer Research.

Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005;104:1548–55.

H. Muss, J. Herrstedt, D. Warr, 2006 .

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

H. Muss, A. Rodgers, F. Skobieranda, 2005, Cancer.

Mastectomy May Be an Inferior Oncologic Approach Compared to Breast Preservation.

G. Gupta, L. Marks, H. Muss, 2019, International journal of radiation oncology, biology, physics.

Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association.

C. Spurr, L. Case, H. Muss, 1991, The New England journal of medicine.

Immunologic Aspects of Chronic Obstructive Pulmonary Disease

D. Berry, C. Cirrincione, H. Muss, 2009 .

VP-16-213 in combination chemotherapy with chest irradiation for small-cell lung cancer: a randomized trial of the Piedmont Oncology Association.

H. Muss, P. Zekan, F. Richards, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer.

H. Cohen, C. Gross, S. Mohile, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Computed tomography versus chest radiography: impact on management of patients with lymphoma.

H. Muss, R. Choplin, N. Wolfman, 1990, Cancer investigation.

Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.

H. Cohen, E. Winer, C. Hudis, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OP-JNCI200081 1..5

E. Winer, J. Bellon, N. Lin, 2020 .

Improved tolerance of vincristine by glutamic acid

C. Spurr, L. Case, H. Muss, 2004, Journal of Neuro-Oncology.

Amelioration of vincristine neurotoxicity by glutamic acid.

J. Atkins, H. Muss, P. Zekan, 1988, The American journal of medicine.

Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: A randomized phase III trial of the Gynecologic Oncology Group

J. Thigpen, R. Mannel, H. Muss, 2003 .

Teniposide (VM‐26) in Patients with Advanced Endometrial Carcinoma A Phase II Trial of the Gynecologic Oncology Group

H. Muss, B. Bundy, L. Adcock, 1991, American journal of clinical oncology.

Methotrexate in Advanced Endometrial Carcinoma: A Phase II Trial of the Gynecologic Oncology Group

K. Hatch, H. Muss, J. Soper, 1990, American journal of clinical oncology.

Mitoxantrone for carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group.

P. Disaia, H. Muss, B. Bundy, 1987, Cancer treatment reports.

Bone marrow evaluation in small cell lung cancer

C. Spurr, H. Muss, M. Cooper, 1984, American journal of clinical oncology.

5-fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma. A phase II trial of the Gynecologic Oncology Group.

H. Muss, K. Degeest, J. Blessing, 1992, American journal of clinical oncology.

Cisplatin-associated cortical blindness.

H. Muss, C. Pippitt, H. Homesley, 1981, Gynecologic oncology.

Interferon therapy for renal cell carcinoma.

H. Muss, 1987, Seminars in oncology.

Echinomycin (NSC 526417) in Advanced Ovarian Cancer: A Phase II Trial of the Gynecologic Oncology Group

V. Baker, H. Muss, J. Blessing, 1990, American journal of clinical oncology.

Teniposide in epithelial ovarian carcinoma: a phase II trial of the Gynecologic Oncology Group.

L. Twiggs, P. Disaia, H. Muss, 1986, Cancer treatment reports.

Mitoxantrone (NSC‐3O1739) in patients with advanced ovarian carcinoma: A phase II study of the Gynecologic Oncology Group

H. Muss, B. Bundy, J. Graham, 1984, American journal of clinical oncology.

A phase II study of PALA (NSC 224131) in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group study.

M. Slavik, H. Muss, B. Bundy, 1984, American journal of clinical oncology.

Phase II clinical study of Yoshi 864 in epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

M. Slavik, H. Muss, J. Blessing, 1982, Cancer treatment reports.

Mitoxantrone in the Treatment of Advanced Uterine Sarcoma: A Phase II Trial of the Gynecologic Oncology Group

H. Muss, B. Bundy, L. Adcock, 1990, American journal of clinical oncology.

Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study.

H. Muss, T. Burke, J. Fowler, 1996, Gynecologic oncology.

Mitoxantrone in the Treatment of Advanced Vulvar and Vaginal Carcinoma: A Gynecologic Oncology Group Study

H. Muss, B. Bundy, W. Christopherson, 1989, American journal of clinical oncology.

Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix.

C. Spurr, H. Muss, M. Cooper, 1977, Obstetrics and Gynecology.

High‐Dose 24‐Hour Infusion of 5‐Fluorouracil in Metastatic Prostate Cancer

J. Brockschmidt, J. Atkins, H. Muss, 1991, American journal of clinical oncology.

Lack of potentiation of vincristine‐induced neurotoxicity by VP‐16–213

C. Spurr, H. Muss, M. Cooper, 1983, American journal of clinical oncology.

Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature

R. Weiss, H. Muss, M. A. Klein, 2004, Cancer Chemotherapy and Pharmacology.

Low dose Ara-C for patients with myelodysplastic syndromes.

H. Muss, B. Powell, D. Buss, 1988, Leukemia.

Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons.

C. Hudis, J. Garber, H. Burstein, 2006, Clinical breast cancer.

Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association.

C. Spurr, L. Case, H. Muss, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vinblastine infusion in non-Hodgkin's lymphomas: lack of total cross-resistance with vincristine.

C. Spurr, H. Muss, P. Zekan, 1987, Cancer investigation.

5‐Fluorouracil with cytosine arabinoside in metastatic gastrointestinal cancer

H. Muss, J. Lokich, E. Frei, 1975, Clinical pharmacology and therapeutics.

Combination chemotherapy with and without the methanol‐extracted residue of bacillus calmette‐guerin (MER) in extensive non‐small‐cell lung cancer: A prospective randomized study for the piedmont oncology association

C. Spurr, H. Muss, M. Cooper, 1981, Cancer.

Methyl‐ccnu, alone and in combination with vincristine, or vincristine and methotrexate, in advanced bronchogenic carcinoma

C. Spurr, H. Muss, M. Cooper, 1976, Cancer.

CCNU in combination chemotherapy for advanced histologically unfavorable non-Hodgkin's lymphoma

C. Spurr, L. Case, H. Muss, 2004, Cancer Chemotherapy and Pharmacology.

Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

Lyndsay Harris, Donald Berry, Larry Norton, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840.

H. Cohen, E. Winer, C. Hudis, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Chloroma and other myeloblastic tumors.

H. Muss, W. Moloney, William C. Moloney, 1973, Blood.

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

Lesley Fallowfield, Mohammad Jahanzeb, Debra L Barton, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endocrine therapy in metastatic breast cancer.

G. Kimmick, H. Muss, 1998, Cancer treatment and research.

Immunotherapy of small cell carcinoma of the lung (SCC): A randomized study

H. Muss, F. Richards, D. Jackson, 1979 .

Cancer Treatment as an Accelerated Aging Process: Assessment, Biomarkers, and Interventions.

L. Jones, H. Muss, A. Hurria, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Synergy In Vitro and in Clinical Trials

T. Morgan, H. Muss, R. Spiegel, 1985 .

Comparative “nocebo effects” in older patients enrolled in cancer therapeutic trials: Observations from a 446‐patient cohort

H. Cohen, J. Foster, R. DeMatteo, 2017, Cancer.

Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.

Barbara L. Smith, D. Berry, E. Winer, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interferon therapy of metastatic renal cell cancer.

H. Muss, 1988, Seminars in surgical oncology.

Platelet phenotype changes associated with breast cancer and its treatment

D. Schneider, H. Muss, M. Wood, 2016, Platelets.

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.

D A Berry, D. Berry, L. Norton, 1998, Journal of the National Cancer Institute.

Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.

L. Case, J. Atkins, H. Muss, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant irradiation following mastectomy: where are we?

H. Muss, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer

H. McLeod, A. Deal, C. Walko, 2018, Cancer Chemotherapy and Pharmacology.

Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology.

H. Bartelink, G. Vlastos, H. Wildiers, 2007, The Lancet. Oncology.

Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.

H. Cohen, D. Berry, E. Winer, 2005, JAMA.

Commentary (Burdette-Radoux/Muss): Psychiatric Assessment and Symptom Management in Elderly Cancer Patients

H. Muss, S. Burdette-Radoux, 2005 .

The role of biological response modifiers in metastatic renal cell carcinoma.

H. Muss, 1988, Seminars in oncology.

Social support and its implications in older, early‐stage breast cancer patients in CALGB 49907 (Alliance A171301)

H. Cohen, A. Wolff, J. Gralow, 2016, Psycho-oncology.

A planned, prospective comparison of short-term quality of life outcomes among older breast cancer patients treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901 ✰

Gretchen, C. Hudis, W. Barry, 2014 .

Optimizing adjuvant chemotherapy in early-stage breast cancer.

E. Perez, H. Muss, 2005, Oncology.

Combination chemotherapy‐radiotherapy with and without the methanol‐extraction residue of bacillus calmette‐guerin (MER) in small cell carcinoma of the lung a prospective randomized trial of the piedmont oncology association

C. Spurr, H. Muss, M. Cooper, 1982, Cancer.

High-dose progestin therapy for metastatic breast cancer.

H. Muss, J. Cruz, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302)

H. Cohen, E. Winer, C. Hudis, 2017, Breast Cancer Research and Treatment.

Intravenous vincristine infusion: Phase I trial

C. Spurr, H. Muss, M. Cooper, 1981, Cancer.

Does walking during chemotherapy impact p16INK4a levels in women with early breast cancer

A. Deal, H. Muss, K. Nyrop, 2022, Journal of clinical laboratory analysis.

Effect of vitamin B12, folate, and dietary supplements on breast carcinoma chemotherapy–induced mucositis and neutropenia

R. Branda, H. Muss, E. M. Brooks, 2004, Cancer.

Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association.

L. Case, J. Atkins, H. Muss, 1996, American journal of clinical oncology.

Tamoxifen as initial endocrine therapy for metastatic breast cancer: Long term follow-up of two Piedmont Oncology Association (POA) trials

L. Case, H. Muss, H. Hoen, 1997, Breast Cancer Research and Treatment.

Autoimmune hemolytic anemia and ovarian dermoid cysts: Case report and review of the literature

H. Muss, H. Homesley, V. Jobson, 1981, Cancer.

Cross-Sectional Analysis of Clinical Trial Availability and North Carolina Neighborhood Social Vulnerability

S. Tuchman, H. Muss, S. Rubinstein, 2022, JCO oncology practice.

A Phase I‐II Study of Recombinant Intrapleural Alpha Interferon in Malignant Pleural Effusions

H. Muss, Robert Barrett, M. Cooper, 1992, American journal of clinical oncology.

Developing a cancer-specific geriatric assessment : A feasibility study

H. Cohen, J. Holland, M. Zauderer, 2005 .

Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia.

C. Spurr, H. Muss, P. Zekan, 1985, Seminars in oncology.

Adriamycin and CCNU in the treatment of advanced breast cancer.

C. Spurr, H. Muss, M. Cooper, 1976, Cancer treatment reports.

Endocrine therapy for advanced breast cancer: A review

H. Muss, 2005, Breast Cancer Research and Treatment.

Perspectives of older women with early breast cancer on telemedicine during post-primary treatment

H. Muss, K. Nyrop, Caroline Buse, 2022, Supportive Care in Cancer.

Quantitation of individual risk for osteoporotic fracture.

W. Wood, H. Muss, 2010, Oncology.

Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations.

H. Cohen, R. Schilsky, K. Schmader, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

J. White, H. Muss, B. Powell, 2009, Scandinavian journal of haematology. Supplementum.

OP-JNCI200081 355..359

E. Winer, J. Bellon, N. Lin, 2021 .

Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond

E. Winer, J. Bellon, N. Lin, 2020, Journal of the National Cancer Institute.

Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

J. Thigpen, R. Mannel, H. Muss, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Granulomatous pneumocystosis presenting as a solitary pulmonary nodule.

K. Geisinger, H. Muss, J. Hartz, 1985, Archives of pathology & laboratory medicine.

Candida tropicalis arthritis and bursitis.

M. Weinblatt, H. Muss, B. Wall, 1982, JAMA.

Clinical trial of pyridoxine to reduce vincristine neurotoxicity

C. Spurr, J. Atkins, H. Muss, 2005, Journal of Neuro-Oncology.

A prospective study of histocompatible leukocyte and platelet transfusions during induction chemotherapy of adult acute nonlymphocytic leukemia.

C. Spurr, H. Muss, M. Cooper, 1981, Medical and pediatric oncology.

Cellular blue nevus simulating metastatic melanoma: Report of an unusually large lesion associated with nevus‐cell aggregates in regional lymph nodes

N. Weidner, H. Muss, J. Sterchi, 1987, Journal of surgical oncology.

Chioroma and Other Myeloblastie Tumors Blood

H. Muss, W. Moloney, 2005 .

Serum alkaline phosphatase determination. Value in the staging of advanced breast cancer.

H. Muss, D. White, V. Howard, 1979, JAMA.

Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-β1) increase invasion rate of tumor cells: a population study

Karen Plaut, Donald Weaver, D. Weaver, 2008, Breast Cancer Research and Treatment.

The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer

L. Case, J. Brockschmidt, H. Muss, 1989, Cancer.

Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease.

D. Chan, G. Hortobagyi, R. Theriault, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nonseminomatous germ cell cancer of the testis. Reducing treatment‐related morbidity in patients with disseminated disease

C. Spurr, H. Muss, M. Cooper, 1982 .

Subcutaneously Administered Recombinant Human Interleukin-2 and Interferon Alfa-2a for Advanced Breast Cancer: A Phase II study of the Cancer and Leukemia Group B (CALGB 9041)

D. Berry, M. Ratain, L. Norton, 2004, Investigational New Drugs.

Recombinant gamma interferon in advanced breast cancer: A phase II trial

H. Muss, P. Zekan, M. Cooper, 2004, Investigational New Drugs.

A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer.

S. Martino, H. Muss, S. Rudnick, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclophosphamide versus cyclophosphamide, methotrexate, and 5‐fluorouracil in advanced prostatic cancer: A randomized trial

M. Resnick, C. Spurr, H. Muss, 1981, Cancer.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Bingshu E. Chen, D. Berry, P. Fasching, 2019, The Lancet.

A phase II trial of high‐dose cytarabine and cisplatin in previously untreated non‐small cell carcinoma of the lung. A piedmont oncology association study

C. Spurr, J. Atkins, H. Muss, 1990, Cancer.

A Phase 11 Trial of High-Dose Cytarabine and Cisplatin in Previously Untreated Non-Small Cell Carcinoma of the Lung

C. Spurr, J. Atkins, H. Muss, 1990 .

The use of interferon in renal cell carcinoma.

H. Muss, 1991, European journal of cancer.

Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration.

H. Muss, R. Pollard, P. Zekan, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer

Timothy Hunter, Scott Tighe, Jeffrey Bond, 2009, Breast Cancer Research and Treatment.

Age-specific changes in intrinsic breast cancer subtypes: a focus on older women.

C. Perou, L. Carey, C. Anders, 2014, The oncologist.

Associations between nutritional factors and chemotherapy toxicity in older adults with solid tumors

C. Gross, S. Mohile, A. Gajra, 2020, Cancer.

Sarcopenia as a predictor of complications and survival following radical cystectomy.

E. Wallen, A. Deal, M. Nielsen, 2014, The Journal of urology.

Cancer and Aging

H. Cohen, H. Muss, A. Hurria, 2016 .

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

D. Berry, A. Thor, W. Wood, 1994, The New England journal of medicine.

Older adult participation in cancer clinical trials: A systematic review of barriers and interventions

H. Cohen, B. Djulbegovic, S. Mohile, 2020, CA: a cancer journal for clinicians.

Prophylactic cranial irradiation in small cell carcinoma of the lung: A Randomized Study

C. Spurr, H. Muss, M. Cooper, 1977 .

Breast Cancer in Older Women

G. Kimmick, H. Muss, 1995, Seminars in oncology.

Phase I study of vincristine and escalating doses of etoposide

C. Spurr, H. Muss, P. Zekan, 1989, Investigational New Drugs.

Combination high-dose etoposide and vincristine infusion

H. Muss, A. Chauvenet, J. Cruz, 2004, Investigational New Drugs.

Pharmacokinetics of vindesine bolus and infusion

C. Spurr, H. Muss, V. Sethi, 2004, Cancer Chemotherapy and Pharmacology.

Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer.

J. Ibrahim, L. Carey, N. Sharpless, 2014, Journal of the National Cancer Institute.

Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement.

Laura A. Levit, H. Cohen, Laura A Levit, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recommendations for a Global Core Curriculum in Medical Oncology.

D. Bajorin, R. Stahel, H. Muss, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Geriatric-assessment-identified functional deficits among adults with multiple myeloma with normal performance status.

W. Wood, S. Tuchman, A. Deal, 2021, Journal of geriatric oncology.

Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.

T. Whelan, S. Martino, N. Robert, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of adjuvant endocrine therapy in early-stage breast cancer.

H. Muss, 2001, Seminars in oncology.

Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.

B. Littenberg, H. Muss, L. Demers, 2011, The oncologist.

Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy.

L. Callahan, H. Muss, M. Altpeter, 2014, Journal of geriatric oncology.

Exercise-induced modulation of monocytes in breast cancer survivors

B. Jensen, C. Battaglini, H. Muss, 2021, Brain, behavior, & immunity - health.

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases

D. Hayes, C. Miller, J. Parker, 2018, Breast Cancer Research and Treatment.

Breast Cancer Prevention

H. Muss, J. F. Noe, 2013 .

Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study.

C K Redmond, V W Chen, C. Redmond, 1994, JAMA.

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

S. Martino, R. Livingston, W. Barlow, 2009, The Lancet.

Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

Dante S. Bortone, D. Bortone, C. Perou, 2022, Journal for ImmunoTherapy of Cancer.

Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study of Sertraline (Zoloft) for the Treatment of Hot Flashes in Women with Early Stage Breast Cancer Taking Tamoxifen

J. Lovato, G. Kimmick, H. Muss, 2006, The breast journal.

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

E. Perez, M. Piccart, S. Martino, 2004, The New England journal of medicine.

Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.

J. J. Miralles, S. Loibl, H. Joensuu, 2022, European journal of cancer.

Thrombocytopenia in Two Patients Treated With Low-Dose Heparin

H. Muss, K. McGrath, J. Stuart, 1978, Obstetrics and gynecology.

A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

E. Perez, M. Piccart, S. Martino, 2003 .

Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer.

H. Muss, S. Yellen, B. Craven, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reactivation of Hand-Schüller-Christian disease six and thirteen years after discontinuation of systemic therapy.

H. Muss, D. Weathers, R. Patterson, 1981, Medical and Pediatric Oncology.

Oxidative metabolism of the human eosinophil.

L. Mcphail, H. Muss, D. Bass, 1977, Blood.

Schistocytes in erythroleukemia.

J. Atkins, H. Muss, 1985, The American journal of the medical sciences.

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.

R. Gralla, H. Muss, A. Rodgers, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved Outcomes From Adding Sequent ia l Pacl i taxe l but Not From Escalat ing Doxorubic in Dose in an Adjuvant Chemotherapy Regimen for Pat ients With Node-Pos i t i ve Pr imary Breast Cancer

D. Berry, R. Schilsky, S. Martino, 2003 .

New strategies for managing metastatic breast cancer.

H. Muss, J. Olin, Julie J. Olin, 2000, Oncology.

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy

T. Weisberg, H. Muss, M. Wood, 2009, Supportive Care in Cancer.

Radionuclide Scanning in Patients with Advanced Malignant Melanoma

H. Muss, P. Barnes, R. Cowan, 1979, Clinical nuclear medicine.

Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls

R. Ziegler, C. Schairer, R. Balasubramanian, 2012, Epigenetics.

Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.

H. Muss, K. Nyrop, T. Nishijima, 2017, The oncologist.

Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum.

K. Courneya, J. Mackey, P. Douglas, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship of flow cytometry results to clinical and steroid receptor status in human breast cancer

H. Muss, T. Kute, D. Case, 1985, Breast Cancer Research and Treatment.

Breast cancer in older patients.

G. Kimmick, H. Muss, 2004, Seminars in oncology.

Flow Cytometry in the Management of Breast Cancer

H. Muss, T. Kute, 1989 .

Phase I/II Trial of Adjuvant Dose‐Dense Docetaxel/Epirubicin/Cyclophosphamide (TEC) in Stage II and III Breast Cancer

T. Ashikaga, H. Muss, M. Wood, 2007, The breast journal.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

T. Whelan, C. Hudis, K. Gelmon, 2016, The New England journal of medicine.

Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.

Barbara L. Smith, D. Berry, E. Winer, 2004, The New England journal of medicine.

Adjuvant Treatment for Older Women with Invasive Breast Cancer

H. Muss, G. Williams, M. Pergolotti, 2016, Women's health.

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.

E. Perez, T. Whelan, S. Martino, 2013 .

Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker

Yi Zhang, Jackie Szymonifka, Dennis C. Sgroi, 2013, Journal of the National Cancer Institute.

A randomized comparative trial of chemotherapy and irradiation therapy for stage ii breast cancer

C. Spurr, H. Muss, M. Cooper, 1981, Cancer.

Frailty and inflammatory markers in older adults with cancer

A. Deal, H. Muss, G. Williams, 2017, Aging.

Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis

T. Funakoshi, H. Muss, Maya Suzuki, 2014, Breast Cancer Research and Treatment.

Standard chemotherapy versus capcitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907.

H. Cohen, D. Berry, E. Winer, 2015 .

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

F. Holmes, J. O’Shaughnessy, J. Pippen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Approach and Management of Breast Cancer in the Elderly.

H. Muss, M. Karuturi, N. VanderWalde, 2016, Clinics in geriatric medicine.

Patient-reported outcomes with PD-1/PD-L1 Inhibitors for advanced cancer: A Meta-Analysis. Running head: PROs with PD-1/PD-L1 Inhibitors

H. Muss, T. Nishijima, Tamura, 2019 .

Patient-Reported Outcomes with PD-1/PD-L1 Inhibitors for Advanced Cancer: A Meta-Analysis.

H. Muss, K. Tamura, T. Nishijima, 2019, The oncologist.

Adjuvant chemotherapy in older women with early-stage breast cancer.

H. Cohen, D. Berry, E. Winer, 2009, The New England journal of medicine.

Hospitalization, and Survival in Patients with MetastaticBreastCancerReceivingTaxane-Based Chemotherapy

A. Deal, H. Muss, M. Weinberg, 2017 .

Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review.

H. Muss, G. Williams, T. Nishijima, 2016, European journal of cancer.

Nodal positivity decreases with age in women with early‐stage, hormone receptor–positive breast cancer

H. Muss, D. Ollila, P. Strassle, 2019, Cancer.

Measuring Biologic Resilience in Older Cancer Survivors.

W. Dale, H. Muss, N. Gilmore, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p16 a biomarker of aging and tolerance for cancer therapy

W. Wood, S. Tuchman, H. Muss, 2020, Translational cancer research.

Frailty Index Developed From a Cancer-Specific Geriatric Assessment and the Association With Mortality Among Older Adults With Cancer.

A. Deal, J. Lund, H. Muss, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer.

H. Cohen, S. Mohile, A. Gajra, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401.

H. Cohen, W. Barry, I. Galinsky, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Developing a cancer‐specific geriatric assessment

H. Cohen, J. Holland, M. Zauderer, 2005, Cancer.

Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.

D. Berry, L. Norton, L. Dressler, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Obesity, Weight Gain, and Weight Management

C. Osterman, H. Muss, K. Nyrop, 2021, Common Issues in Breast Cancer Survivors.

Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer

C. Anders, E. Dees, A. Deal, 2018, Breast Cancer Research and Treatment.

Geriatric assessment as an aide to understanding falls in older adults with cancer

A. Deal, H. Muss, G. Williams, 2015, Supportive Care in Cancer.

A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.

C. Spurr, L. Case, H. Muss, 1985, Cancer.

Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.

D. Berry, E. Winer, E. Perez, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Electronic Geriatric Assessment: Is It Feasible in a Multi-Institutional Study That Included a Notable Proportion of Older African American Patients? (Alliance A171603).

H. Cohen, J. Sloan, A. Shahrokni, 2021, JCO clinical cancer informatics.

A randomized trial of adjuvant chemotherapy and immunotherapy in stage I and stage II cutaneous melanoma. An interim report

C. Spurr, L. Case, H. Muss, 1985 .

Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.

C. Spurr, H. Muss, M. Cooper, 1978, Cancer treatment reports.

Weight trajectories in women receiving systemic adjuvant therapy for breast cancer

L. Carey, A. Deal, H. Muss, 2019, Breast Cancer Research and Treatment.

Neoadjuvant therapy for advanced squamous cell carcinoma of the cervix: cisplatin followed by radiation therapy--a pilot study of the Gynecologic Oncology Group.

H. Muss, H. Homesley, C. Ferree, 1987, Gynecologic oncology.

Sequential hemibody irradiation integrated into a chemotherapy-local radiotherapy program for limited disease small cell lung cancer.

L. Case, H. Muss, R. Choplin, 1986, International journal of radiation oncology, biology, physics.

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

D. Berry, E. Winer, E. Perez, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination cisplatin and carboplatin in advanced squamous cell carcinoma of the head and neck.

H. Muss, G. Russell, B. Powell, 1996, Cancer Investigation.

Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907

H. Cohen, E. Winer, C. Hudis, 2008 .

Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: A randomized double-blind trial in 866 patients.

R. Gralla, H. Muss, A. Rodgers, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase Ib trial of lenalidomide as post-remission therapy for older adults with acute myeloid leukemia: Safety and longitudinal assessment of geriatric functional domains

A. Ivanova, A. Deal, H. Muss, 2021, Journal of Geriatric Oncology.

Accelerated aging among childhood, adolescent, and young adult cancer survivors is evidenced by increased expression of p16INK4a and frailty

W. Wood, A. Deal, H. Muss, 2020, Cancer.

Vincristine infusion with CHOP-CCNU in diffuse large-cell lymphoma.

C. Spurr, H. Muss, B. Powell, 1990, Cancer investigation.

Vincristine infusion in refractory gynecologic malignancies.

H. Muss, H. Homesley, F. Richards, 1986, Gynecologic Oncology.

Treatment of advanced non‐Hodgkin's lymphoma with vincristine infusion

C. Spurr, H. Muss, M. Cooper, 1984, Cancer.

Pharmacokinetics of vincristine infusion.

C. Spurr, H. Muss, M. Cooper, 1981, Cancer treatment reports.

Dose-Response T rial o f M egestrol A cetate i n A dvanced Breast C ancer: C ancer a nd L eukemia G roup B Phase I II S tudy 8 741

D. Berry, L. Norton, J. Abrams, 1999 .

Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741.

D. Berry, L. Norton, J. Abrams, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trials of high-dose cytosine arabinoside (HDara-C) and HDara-C plus cisplatin in patients with advanced malignancies.

D. Ferree, J. Atkins, H. Muss, 1985, Seminars in oncology.

Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies

C. Spurr, J. Atkins, H. Muss, 1987, Cancer Chemotherapy and Pharmacology.

Mitoxantrone and high-dose ara-C in refractory malignancies: a phase I trial.

H. Muss, P. Zekan, B. Powell, 1989, Medical and pediatric oncology.

Ara-C syndrome during low-dose continuous infusion therapy.

H. Muss, P. Zekan, B. Powell, 1986, Medical and Pediatric Oncology.

Infusion of etoposide and vincristine in non-Hodgkin's lymphoma.

C. Spurr, H. Muss, B. Powell, 1989, Selective cancer therapeutics.

Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840.

H. Cohen, E. Winer, C. Hudis, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Patient‐reported and clinician‐reported chemotherapy‐induced peripheral neuropathy in patients with early breast cancer: Current clinical practice

L. Carey, E. Basch, W. Wood, 2019, Cancer.

Therapy of advanced colorectal carcinoma with 5‐fluorouracil and cyclophosphamide in combination with either CCNU or methotrexate

C. Spurr, H. Muss, M. Cooper, 1980, Cancer.

Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association

H. Muss, H. Hoen, D. Jackson, 2004, Cancer Chemotherapy and Pharmacology.

Vincristine by continuous infusion in refractory breast cancer: a phase II study.

H. Muss, M. Cooper, H. Wells, 1983, American journal of clinical oncology.

Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment].

L. Case, H. Muss, V. Stanley, 1992, JAMA.

A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.

J. Doroshow, J. Bennett, H. Muss, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.

M. Citron, J. Abrams, C. Cirrincione, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High‐dose cyclophosphamide and 5‐fluorouracil versus vincristine, doxorubicin, and cyclophosphamide in advanced carcinoma of the breast: A phase III study of the piedmont oncology association (POA)

C. Spurr, L. Case, H. Muss, 1984, Cancer.

Vincristine, doxorubicin, and cyclophosphamide versus low‐dose intravenous cyclophosphamide, methotrexate, and 5‐fluorouracil in advanced breast cancer. A randomized trial of the piedmont oncology association

C. Spurr, H. Muss, M. Cooper, 1982, Cancer.

Combination chemotherapy in advanced breast cancer.: a randomized trial comparing a three-vs a five-drug program.

C. Spurr, H. Muss, M. Cooper, 1977, Archives of internal medicine.

Extended adjuvant endocrine therapy in breast cancer: current status and future directions.

T. Whelan, J. Ingle, P. Goss, 2008, Clinical breast cancer.

Abstract GS6-04: Development and validation of a chemotherapy toxicity (Chemo Tox) risk score for older patients (Pts) with breast cancer (BC) receiving adjuvant/neoadjuvant treatment (Adjuvant Tx): A R01 and BCRF funded prospective multicenter study

H. Cohen, C. Gross, W. Dale, 2019, General Session Abstracts.

CCNU, bleomycin, and methylprednisolone with or without adriamycin in renal cel carcinoma: a randomized trial.

C. Spurr, H. Muss, M. Cooper, 1977, Cancer treatment reports.

Oncology pharmacist-led medication reconciliation among cancer patients initiating chemotherapy

J. Lund, H. Muss, H. Sanoff, 2019, Journal of Oncology Pharmacy Practice.

The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women

J. Garber, H. Muss, M. Wood, 2016, Cancer Prevention Research.

The association of increased weight, body mass index, and tissue density with the risk of breast carcinoma in Vermont

B. Geller, P. Vacek, H. Muss, 2000, Cancer.

Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient.

H. Muss, R. Freedman, 2014, Journal of geriatric oncology.

A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer

L. Carey, G. Kimmick, H. Muss, 2022, npj Breast Cancer.

A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer

L. Carey, G. Kimmick, H. Muss, 2022, medRxiv.

Age and the Risk of Paclitaxel‐Induced Neuropathy in Women with Early‐Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101

H. Cohen, B. Ramaswamy, L. Shulman, 2018, The oncologist.

A phase II single‐arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects

L. Carey, E. Dees, A. Deal, 2023, Cancer medicine.

Older Adults with Cancer: A Randomized Controlled Trial of Occupational and Physical Therapy

E. Basch, B. Reeve, A. Deal, 2019, Journal of the American Geriatrics Society.

Impact of Acute Intermittent Exercise on Natural Killer Cells in Breast Cancer Survivors

R. Mcmurray, S. Randell, A. Deal, 2015, Integrative cancer therapies.

Developing a clinical and biological measures of aging core: Cancer and aging research group infrastructure.

S. Mohile, W. Dale, Margaret Sedenquist, 2020, Journal of geriatric oncology.

Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study

H. Cohen, E. Winer, C. Hudis, 2018, Breast Cancer Research and Treatment.

Occupational Therapy for Adults With Cancer: Why It Matters

Mackenzi Pergolotti, H. Muss, G. Williams, 2016, The oncologist.

Approach to the older patient with stage II/III colorectal cancer: who should get curative-intent therapy?

H. Muss, H. Sanoff, E. Ramsdale, 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer

A. Wolff, H. Burstein, J. Mandelblatt, 2019, Journal of the American Geriatrics Society.

Association between patient‐reported hearing and visual impairments and functional, psychological, and cognitive status among older adults with cancer

H. Cohen, C. Gross, S. Mohile, 2018, Cancer.

The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance).

H. Cohen, K. Ballman, B. Parker, 2018, Journal of geriatric oncology.

A randomized study of two five drug regimens in advanced breast cancer

C. Spurr, H. Muss, M. Cooper, 1976 .

Adjuvant chemotherapy in older women with breast cancer: who and what?

H. Muss, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines.

D V Schapira, E Grunfeld, M. Somerfield, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postoperative Follow‐up After Early‐Stage Breast Cancer

H. Muss, 1996 .

Postoperative follow‐up of patients with early breast cancer. Patterns of care among clinical oncologists and a review of the literature

J. Brockschmidt, G. Saylor, H. Muss, 1991, Cancer.

A retrospective study on prephase therapy prior to definitive multiagent chemotherapy in aggressive lymphomas

H. Muss, A. Beaven, C. Dittus, 2018, Leukemia & lymphoma.

Elderly patients with squamous cell carcinoma of the head and neck and the benefit of multimodality therapy.

D. Hayes, N. Zhao, H. Muss, 2015, The oncologist.

Selecting adjuvant endocrine therapy for breast cancer.

H. Muss, M. Wood, J. Eneman, 2004, Oncology.

Physical activity communication between oncology providers and patients with early‐stage breast, colon, or prostate cancer

A. Deal, H. Muss, G. Williams, 2016, Cancer.

Surveillance Mammography in Older Patients With Breast Cancer—Can We Ever Stop?: A Review

E. Winer, N. Keating, A. Partridge, 2017, JAMA oncology.

Mammography in Older Breast Cancer Survivors: Can We Ever Stop?

E. Winer, N. Keating, A. Partridge, 2017 .

A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B‐cell lymphoma

A. Ivanova, A. Deal, K. Richards, 2016, British journal of haematology.

Abstract P5-21-08: Tolerability of the combination of lapatinib and trastuzumab in older patients with HER2 positive metastatic breast cancer

J. Waisman, G. Kimmick, H. Muss, 2018 .

Treatment of Metastatic Breast Cancer in Women Aged 65 Years and Older

H. Muss, G. Williams, T. Jolly, 2012, Women's health.

Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).

H. Cohen, J. Byrd, J. Leonard, 2018, Journal of geriatric oncology.

Case records of the Massachusetts General Hospital. Case 15-2010. An 85-year-old woman with mammographically detected early breast cancer.

H. Muss, E. Brachtel, H. D’Alessandro, 2010, The New England journal of medicine.

Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients

P. Spanheimer, H. Muss, D. Ollila, 2021, Breast Cancer Research and Treatment.

Individualizing Local-Regional Therapy of Breast Cancer in the Elderly

H. Muss, K. McGuire, K. Gallagher, 2018, Current Breast Cancer Reports.

Breast Cancer in the Older Adult

H. Muss, Emily J. Guerard, Madhuri V. Vithala, 2016 .

Adjuvant therapy of breast cancer in women 70 years of age and older: tough decisions, high stakes.

H. Muss, E. Jones, Ashley N Leak, 2012, Oncology.

Adjuvant therapy in the elderly: making the right decision.

D. Sargent, M. Aapro, H. Muss, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review

H. Muss, G. Williams, K. Nyrop, 2019, Breast Cancer Research and Treatment.

Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker

M. Erlander, D. Sgroi, P. Porter, 2013, Journal of the National Cancer Institute.

Management of the frail elderly with breast cancer.

H. Muss, K. Dittus, 2007, Oncology.

Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance)

H. Cohen, E. Winer, C. Hudis, 2017, Breast Cancer Research and Treatment.

Echinomycin in Recurrent and Metastatic Endometrial Carcinoma: A Phase II Trial of the Gynecologic Oncology Group

H. Muss, J. Blessing, B. Dubeshter, 1993, American journal of clinical oncology.

Paris and New York: more in common than you think!

H. Muss, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial.

E. Perez, T. Whelan, S. Martino, 2009 .

Management of disseminated disease in the patient with bladder cancer.

H. Muss, J. Perry, 1994, The Urologic clinics of North America.

Time‐to‐Treatment‐Failure and Related Outcomes Among 1000+ Advanced Non–Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711)

H. Cohen, M. Edelman, J. Feliciano, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chemotherapy Toxicity Risk Score for Treatment Decisions in Older Adults with Advanced Solid Tumors.

A. Deal, H. Muss, H. Sanoff, 2018, The oncologist.

Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901

H. Cohen, E. Winer, C. Hudis, 2014, Journal of Cancer Survivorship.

Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.

L. Carey, E. Basch, W. Wood, 2018, The oncologist.

Patient-Reported Comorbidity and Survival in Older Adults with Cancer.

A. Deal, J. Lund, H. Muss, 2017, The oncologist.

Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.

H. Cohen, E. Winer, C. Hudis, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians.

H. Cohen, E. Winer, S. Edge, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Congruence of patient‐ and clinician‐reported toxicity in women receiving chemotherapy for early breast cancer

L. Carey, E. Basch, W. Wood, 2020, Cancer.

Adjuvant chemotherapy in older patients with stage III colon cancer: an underused lifesaving treatment.

Debra L. Bynum, H. Muss, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial

H. Cohen, C. Gross, G. Lyman, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)

H. Cohen, E. Winer, C. Hudis, 2017, Breast Cancer Research and Treatment.

Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance).

H. Cohen, E. Winer, C. Hudis, 2014, Journal of oncology practice.

Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802).

A. Zaslavsky, E. Lamont, Menggang Yu, 2014, Journal of geriatric oncology.

Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907

H. Cohen, E. Winer, C. Hudis, 2013, Breast Cancer Research and Treatment.

Geriatric assessment-identified deficits in older cancer patients with normal performance status.

W. Wood, A. Deal, Trevor, 2015, The oncologist.

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.

H. Cohen, D. Berry, E. Winer, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changes in Monocyte Populations Following Acute Aerobic Exercise in Breast Cancer Survivors

H. Muss, D. Bartlett, N. Khosravi, 2018 .

The role of adjuvant radiation treatment in older women with early breast cancer.

H. Muss, N. VanderWalde, B. Hebert, 2013, Journal of geriatric oncology.

Cancer in the oldest old: making better treatment decisions.

L. Hanson, H. Muss, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial

E. Perez, M. Piccart, S. Martino, 2006, Breast Cancer Research and Treatment.

The role of chemotherapy and adjuvant therapy in the management of breast cancer in older women

H. Muss, 1994, Cancer.

Baseline fatigue in early breast cancer survivors: understanding its prevalence in community-based exercise

C. Battaglini, H. Muss, Z. Kerr, 2022, Supportive Care in Cancer.

A randomized trial of chemotherapy (L-PAM vs CMF) and irradiation for node positive breast cancer

C. Spurr, J. Brockschmidt, H. Muss, 1991, Breast Cancer Research and Treatment.

Use of Single-Item Self-Rated Health Measure to Identify Frailty and Geriatric Assessment-Identified Impairments Among Older Adults with Cancer

S. Bhatia, H. Muss, G. Williams, 2022, The oncologist.

Managing early-stage breast cancer in your older patients.

H. Muss, S. Witherby, 2006, Oncology.

Megestrol acetate as primary hormonal therapy for advanced breast cancer.

J. V. Von Roenn, J. Wolter, H. Muss, 1988, Seminars in oncology.

Tailored Systemic Therapy for the Elderly Woman

H. Muss, C. Holmes, 2006 .

Update in medical oncology for older patients: focus on breast cancer: management of early breast cancer.

H. Muss, S. Witherby, 2005, Cancer journal.

Internet tools to enhance breast cancer care

H. Muss, S. S. Shachar, 2016, npj Breast Cancer.

Relationship Between Mammographic Features and Hormone Receptor Content in Patients With Breast Cancer

L. Case, H. Muss, R. Choplin, 1989, Southern medical journal.

Recommendations for a global core curriculum in medical oncology.

D. Bajorin, R. Stahel, H. Muss, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The underutilization of occupational and physical therapy for older adults with cancer.

B. Reeve, A. Deal, H. Muss, 2014 .

A Randomized Trial of Real-Time Geriatric Assessment Reporting in Nonelectively Hospitalized Older Adults with Cancer.

J. Busby‐Whitehead, A. Deal, H. Muss, 2020, The oncologist.

From Assessment to Implementation and Beyond in Cancer and Aging Research.

H. Cohen, H. Muss, W. Tew, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma: A phase II study of the Gynecologic Oncology Group

K. Hatch, G. Sutton, H. Muss, 1985, American journal of clinical oncology.

Tamoxifen rechallenge: response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer.

H. Muss, M. Cooper, H. Muss, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prevalence of potentially modifiable functional deficits and the subsequent use of occupational and physical therapy by older adults with cancer.

B. Reeve, A. Deal, H. Muss, 2015, Journal of geriatric oncology.

Establishing physical activity in breast cancer: self-report versus activity tracker

W. Wood, A. Deal, H. Muss, 2019, Breast Cancer Research and Treatment.

Echinomycin (NSC 526417) in recurrent and metastatic squamous cell carcinoma of the cervix

H. Muss, J. Blessing, R. McGehee, 1992, Investigational New Drugs.

Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients.

T. Morgan, H. Muss, B. Powell, 1989, Leukemia.

Serial Assessment of Depression and Anxiety by Patients and Providers in Women Receiving Chemotherapy for Early Breast Cancer.

A. Deal, H. Muss, K. Nyrop, 2020, The oncologist.

Body mass index and patient-reported function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancer

W. Wood, E. Dees, A. Deal, 2023, Supportive Care in Cancer.

Anticipating mental health needs after chemotherapy in early-stage breast cancer using patient-reported symptom screening

A. Deal, H. Muss, K. Nyrop, 2022, Supportive Care in Cancer.

Clinician-observed and patient-reported toxicities and their association with poor tolerance to therapy in older patients with head and neck or lung cancer treated with curative radiotherapy.

A. Deal, H. Muss, B. Chera, 2019, Journal of geriatric oncology.

Randomized phase II study of a home-based walking intervention for radiation-related fatigue among older adult breast cancer patients.

M. Ballo, M. Koçak, A. Deal, 2020, Journal of geriatric oncology.

Written informed consent in patients with breast cancer

C. Spurr, H. Muss, M. Cooper, 1979, Cancer.

Impact of the Cancer and Aging Research Group score and treatment intensity on survival and toxicity outcomes in older adults with advanced noncolorectal gastrointestinal cancers

A. Deal, H. Muss, H. Sanoff, 2022, Cancer.

Factors used to select adjuvant therapy of breast cancer in the United States: an overview of age, race, and socioeconomic status.

H. Muss, 2001, Journal of the National Cancer Institute. Monographs.

Recent Advances: Adjuvant Therapy for Older Women With Breast Cancer

H. Muss, W. C. Taylor, 2010, Cancer journal.

Adjuvant chemotherapy of breast cancer in the older patient.

H. Muss, W. C. Taylor, 2010, Oncology.

Adjuvant therapy for older women with breast cancer.

H. Muss, 2003, Breast.

Management of older women with early-stage breast cancer.

K. Hughes, H. Muss, R. Punglia, 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Aromatase inhibitor associated arthralgia: the importance of oncology provider-patient communication about side effects and potential management through physical activity

L. Callahan, C. Rini, H. Muss, 2016, Supportive Care in Cancer.

A phase II trial of peg-L-asparaginase in the treatment of non-hodgkins lymphoma

C. Spurr, H. Muss, P. Zekan, 1990, Investigational New Drugs.

Associations of functional, psychosocial, and medical factors with cognitive impairment in older, chemotherapy naïve patients with early breast cancer

A. Deal, H. Muss, K. Nyrop, 2020, Psycho-oncology.

Associations of functional, psychosocial, and medical factors with cognitive impairment in older, chemotherapy-naïve patients with early breast cancer.

A. Deal, H. Muss, K. Nyrop, 2020 .

Association between a cognitive screening test and severe chemotherapy toxicity in older adults with cancer.

C. Gross, S. Mohile, R. Jayani, 2019, Journal of geriatric oncology.

Associations of functional, psychosocial, medical, and socio‐demographic factors with cognitive screening in chemotherapy naïve patients with breast cancer

W. Wood, A. Deal, H. Muss, 2018, Psycho-oncology.

Feasibility of geriatric assessment in community oncology clinics.

A. Deal, H. Muss, G. Williams, 2014, Journal of geriatric oncology.

Older women with breast cancer: slow progress, great opportunity, now is the time.

J. Busby‐Whitehead, H. Muss, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weight change in postmenopausal breast cancer survivors: Independent effects of adjuvant tamoxifen and aromatase inhibitors.

A. Deal, H. Muss, K. Nyrop, 2016 .

Geriatric Assessment Predicts Hospitalization Frequency and Long-Term Care Use in Older Adult Cancer Survivors.

A. Deal, J. Lund, H. Muss, 2019, Journal of oncology practice.

Abstract GS1-07: Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients

J. J. Miralles, S. Loibl, M. Mackelenbergh, 2020 .

The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer

A. Deal, H. Muss, G. Williams, 2020, Breast Cancer Research and Treatment.

Association of body composition with function in women with early breast cancer

A. Deal, H. Muss, G. Williams, 2020, Breast Cancer Research and Treatment.

Beyond sarcopenia: Characterization and integration of skeletal muscle quantity and radiodensity in a curable breast cancer population

A. Deal, H. Muss, G. Williams, 2018, The breast journal.

Myosteatosis evaluation using erector spinae and psoas muscles to predict adverse events during adjuvant chemotherapy for breast cancer

A. Deal, H. Muss, G. Williams, 2021, Breast Cancer Research and Treatment.

Research Methods: Translational Research in Geriatric Oncology

H. Muss, G. Williams, S. S. Shachar, 2018 .

African American Cancer Survivors

H. Muss, J. Crandell, B. Pierre-Louis, 2015, Journal of transcultural nursing : official journal of the Transcultural Nursing Society.

Obesity, comorbidities, and treatment selection in Black and White women with early breast cancer

L. Carey, A. Deal, H. Muss, 2020, Cancer.

Special Issues in Older Women with Breast Cancer.

H. Muss, A. Hurria, 2015, Advances in experimental medicine and biology.

Long-Term Follow-Up of a Phase II Trial Studying a Weekly Doxorubicin-Based Multiple Drug Adjuvant Therapy for Stage II Node-Positive Carcinoma of the Breast

L. Case, G. Kimmick, H. Muss, 2002, Breast Cancer Research and Treatment.

Chemotherapy of advanced ovarian epithelial carcinoma with melphalan and levamisole: a pilot study of the Gynecologic Oncology Group.

C. Spurr, H. Muss, H. Homesley, 1981, American journal of obstetrics and gynecology.

Risk Factors for Hospitalizations Among Older Adults with Gastrointestinal Cancers

C. Gross, S. Mohile, A. Gajra, 2022, The oncologist.

Healthcare satisfaction in older and younger patients with cancer.

A. Deal, L. Hanson, H. Muss, 2016, Journal of geriatric oncology.

Targeted Therapies in Older Adults With Breast Cancer: What Do We Know?

H. Muss, A. Hurria, Shlomit Strulov Shachar, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Esorubicin (4′‐Deoxydoxorubicin, NSC 267469) in Advanced Breast Cancer: A Phase II Study of the CALGB

W. Wood, N. Vogelzang, I. Henderson, 1990, American journal of clinical oncology.

Brain scanning in patients with recurrent breast cancer

H. Muss, D. White, R. Cowan, 1976, Cancer.

Cytotoxic agents in the treatment of rheumatoid arthritis.

H. Muss, R. Turner, J. Davis, 1978, Southern medical journal.

Challenges in the treatment of older breast cancer patients.

H. Muss, G. Williams, Ellen Jones, 2013, Hematology/oncology clinics of North America.

Special issues related to breast cancer adjuvant therapy in older women.

H. Muss, S. Witherby, 2005, Breast.

A randomized controlled trial of outpatient CAncer REhabilitation for older adults: The CARE Program.

B. Reeve, A. Deal, H. Muss, 2015, Contemporary clinical trials.

Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance)

H. Cohen, C. Isaacs, J. Clapp, 2017, Breast Cancer Research and Treatment.

Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869.

D. Berry, C. Cirrincione, H. Muss, 1995, Cytometry.

Geriatric Assessment as a Predictor of Tolerance, Quality of Life, and Outcomes in Older Patients With Head and Neck Cancers and Lung Cancers Receiving Radiation Therapy.

E. Basch, B. Reeve, J. Tepper, 2017, International journal of radiation oncology, biology, physics.

A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901.

H. Cohen, E. Winer, C. Hudis, 2013, Journal of geriatric oncology.

The influence of aging on the early detection, diagnosis, and treatment of breast cancer

H. Muss, Marisa Siebel, 2005, Current oncology reports.

Evaluating the association between adjuvant chemotherapy and function-related adverse events among older patients with early stage breast cancer.

Phyo T. Htoo, J. Lund, H. Muss, 2017, Journal of geriatric oncology.

Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma

R. Motzer, M. Ginsberg, R. Amato, 2003, Investigational New Drugs.

Adjuvant treatment of elderly breast cancer patients.

H. Muss, 2007, Breast.

Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.

Dongsheng Tu, Martine J Piccart, James N Ingle, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors

L. Callahan, H. Muss, Betsy Hackney, 2017, The oncologist.

Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001.

H. Cohen, J. Mandelblatt, B. Peterson, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Actinomycin D in the treatment of advanced breast cancer

C. Spurr, H. Muss, M. Cooper, 2004, Cancer Chemotherapy and Pharmacology.

Spinal cord compression in breast cancer

H. Muss, M. Ball, D. Case, 1985, Cancer.

Adjuvant chemotherapy for older women with breast cancer

H. Muss, 2008 .

Self-directed physical activity intervention in older adults undergoing adjuvant chemotherapy for colorectal cancer: Design of a randomized controlled trial.

A. Deal, H. Muss, H. Sanoff, 2015, Contemporary clinical trials.

Long‐term trajectories of self‐reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance)

H. Cohen, B. Pitcher, C. Isaacs, 2016, Cancer.

Geriatric assessment for oncologists: rationale and future directions.

M. Lachs, H. Muss, A. Kornblith, 2006, Critical reviews in oncology/hematology.

The Effects of Exercise on Patient-Reported Outcomes and Performance-Based Physical Function in Adults With Acute Leukemia Undergoing Induction Therapy: Exercise and Quality of Life in Acute Leukemia (EQUAL)

W. Wood, B. Reeve, A. Deal, 2017, Integrative cancer therapies.

Cancer in the elderly: a societal perspective from the United States.

H. Muss, 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

Interferon and doxorubicin in renal cell carcinoma.

C. Spurr, H. Muss, M. Cooper, 1985, Cancer treatment reports.

Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27

T. Whelan, K. Gelmon, J. Ingle, 2016, Breast Cancer Research and Treatment.

Impact of community-based exercise program participation on aerobic capacity in women with and without breast cancer

B. Jensen, C. Battaglini, H. Muss, 2021, World journal of clinical oncology.

Person‐centered communication about weight and weight management: Focus group discussions in a diverse sample of women with nonmetastatic breast cancer and obesity

H. Muss, Randall Teal, Kathryn Stein, 2021, Cancer.

Echinomycin (NSC 526417) in recurrent and metastatic nonsquamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.

H. Muss, P. Hanjani, J. Blessing, 1992, American journal of clinical oncology.

Informed consent: Patient information forms in chemotherapy trials

C. Spurr, H. Muss, M. Cooper, 1984, American journal of clinical oncology.

Survival in Older Japanese Adults With Advanced Cancer Before and After Implementation of a Geriatric Oncology Service.

M. Morita, H. Muss, Y. Toh, 2023, JCO oncology practice.

Comprehensive geriatric assessment: Valuation and patient preferences in older Japanese adults with cancer

M. Morita, H. Muss, Y. Toh, 2022, Journal of the American Geriatrics Society.

Falls in Older Adults With Cancer: Evaluation by Oncology Providers.

A. Deal, H. Muss, G. Williams, 2015, Journal of oncology practice.

Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer.

Karla Kerlikowske, Les Irwig, Diana L Miglioretti, 2011, JAMA.

Response to "Body composition analysis via single slice computed tomography analysis - The shortcomings".

H. Muss, J. Broughman, G. Williams, 2016, Journal of geriatric oncology.

5-fluorouracil and low-dose leucovorin in the treatment of recurrent squamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.

E. Partridge, H. Muss, J. Blessing, 1992, American journal of clinical oncology.

Evaluation of falls in older adults in a comprehensive cancer center: How are we doing?

A. Deal, H. Muss, G. Williams, 2014 .

Learning from big data: are we undertreating older women with high-risk breast cancer?

J. Sparano, H. Muss, 2016, npj Breast Cancer.

Adaptation of an Evidence-Based Arthritis Program for Breast Cancer Survivors on Aromatase Inhibitor Therapy Who Experience Joint Pain

L. Callahan, C. Rini, H. Muss, 2015, Preventing chronic disease.

Impairment and Longitudinal Recovery of Older Adults Treated with Radical Cystectomy for Muscle-Invasive Bladder Cancer.

M. Milowsky, A. Deal, M. Nielsen, 2020, The Journal of urology.

Breast cancer and aging: results of the U13 conference breast cancer panel

A. Shahrokni, G. Kimmick, H. Muss, 2014, Breast Cancer Research and Treatment.

Competing risks of death in younger and older postmenopausal breast cancer patients.

K. Gelmon, J. Ingle, P. Goss, 2014, World journal of clinical oncology.

Nonseminomatous germ‐cell cancer of the testis. Reducing treatment‐related morbidity in patients with disseminated disease

C. Spurr, H. Muss, D. Jackson, 1982, Cancer.

Age and competing concerns in treatment selection for women with non-metastatic HR+ and HER2- breast cancer: Current clinical practice.

A. Deal, H. Muss, Sanah N. Vohra, 2022, Journal of geriatric oncology.

Accuracy of screening mammography in older women.

Benjamin Littenberg, Natalie Sinclair, B. Littenberg, 2011, AJR. American journal of roentgenology.

Functional age and tolerance to radiotherapy: A prospective study of a Comprehensive Geriatric Assessment.

A. Deal, H. Muss, B. Chera, 2015 .

Frail young adult cancer survivors experience poor health‐related quality of life

A. Deal, H. Muss, H. Nichols, 2022, Cancer.

Current status of endocrine therapy for metastatic breast cancer.

G. Kimmick, H. Muss, 1995, Oncology.

Treatment plans for black and white women with stage II node‐positive breast cancer: The national cancer institute black/white cancer survival study experience

V W Chen, B. Edwards, R. Kurman, 1992, Cancer.

P16(INK4a)expression after chemotherapy in older women with early-stage breast cancer.

L. Carey, N. Sharpless, C. Anders, 2011 .

Vinblastine and 6-thioguanine in the treatment of advanced breast cancer.

C. Spurr, H. Muss, F. Richards, 1978, Cancer treatment reports.

A randomized controlled trial of an educational program to improve accrual of older persons to cancer treatment protocols: CALGB 360001.

J. Mandelblatt, G. Kimmick, H. Muss, 2004, Journal of Clinical Oncology.

Mental status evaluation in older adults with cancer: Development of the Mental Health Index-13.

A. Deal, H. Muss, G. Williams, 2019, Journal of geriatric oncology.

The incremental value of a geriatric assessment-derived three-item scale on estimating overall survival in older adults with cancer.

A. Deal, J. Lund, H. Muss, 2018, Journal of geriatric oncology.

Infrastructure to Support Accrual of Older Adults to National Cancer Institute Clinical Trials.

G. Kimmick, W. Dale, H. Muss, 2022, Journal of the National Cancer Institute. Monographs.

Prevalence of sarcopenia in older patients with colorectal cancer.

A. Deal, H. Muss, J. Broughman, 2015, Journal of geriatric oncology.

Construction of a frailty index for older adults with cancer using a geriatric assessment.

W. Wood, A. Deal, H. Muss, 2015 .

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)

H. Cohen, D. Berry, E. Winer, 2016, Breast Cancer Research and Treatment.

Management of Triple-Negative Breast Cancer in Older Patients: How Is It Different?

H. Muss, T. Jolly, Ellen Jones, 2018, Oncology.

Paradigm Shift in Adjuvant Treatment of Receptor Positive Premenopausal Breast Cancer Patients ? Not Yet !

Barbara L. Smith, D. Berry, E. Winer, 2003 .

A 10-item frailty index based on a comprehensive geriatric assessment (FI-CGA-10) in older adults with cancer: development and construct validation.

M. Morita, H. Muss, Y. Toh, 2021, The oncologist.

Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research Group

H. Cohen, C. Gross, S. Mohile, 2018, Supportive Care in Cancer.

High-dose cyclophosphamide and fluorouracil (CF) versus vincristine (V), doxorubicin (A), and cyclophosphamide (C) as first line therapy for advanced breast carcinoma

H. Muss, P. Zekan, E. Pope, 1982 .

Preoperative breast MRI and surgical outcomes in elderly women with invasive ductal and lobular carcinoma: a population-based study

Stephanie B. Wheeler, William R. Carpenter, Anne-Marie Meyer, 2013, Breast Cancer Research and Treatment.

Psychosocial predictors of depression among older African American patients with cancer.

Nakia C. Best, A. Deal, H. Muss, 2013, Oncology nursing forum.

Exercise training partially rescues impaired mucosal associated invariant t-cell mobilization in breast cancer survivors compared to healthy older women

B. Jensen, A. Deal, C. Battaglini, 2021, Experimental Gerontology.

Concurrent chemotherapy and single high-dose plus whole abdominopelvic radiation for persistent ovarian carcinoma.

H. Muss, C. Scarantino, H. Homesley, 1989, Gynecologic oncology.

Targeted therapy for metastatic breast cancer.

H. Muss, 2006, The New England journal of medicine.

Geriatric assessment to predict hospitalization frequency and long-term care utilization in older adult cancer survivors.

A. Deal, J. Lund, H. Muss, 2018 .

Biopsy of breast cancer metastases: patient characteristics and survival

G. Bar-Sela, H. Muss, K. Drumea, 2017, BMC Cancer.

Bioelectrical Impedance Analysis for the Assessment of Sarcopenia in Patients with Cancer: A Systematic Review.

C. Battaglini, H. Muss, G. Williams, 2020 .

Meeting the needs of the aging population: The canadian network on aging and cancer—report on the first network meeting, 27 april 2016

S. Mohile, S. Alibhai, E. Szumacher, 2017 .

Geriatric oncology for the 21st century: a call for action.

B. Moy, T. Flaig, H. Muss, 2014, Journal of oncology practice.

A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.

E. Winer, T. Whelan, C. Hudis, 2016 .

Hormonal therapy of breast cancer: state of the art.

H. Muss, B. Murphy, 1997, Oncology.

Predictors of Unplanned Hospitalizations Among Older Adults Receiving Cancer Chemotherapy

H. Cohen, C. Gross, S. Mohile, 2021, JCO oncology practice.

Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer.

J L Pater, M. Piccart, S. Martino, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erratum: Multidisciplinary Management of Breast Cancer During Pregnancy.

C. Anders, H. Muss, K. McGuire, 2018, The oncologist.

Echinomycin (NSC 526417) in Squamous‐Cell Carcinoma of the Cervix: A Phase II Trial of the Gynecologic Oncology Group

H. Muss, J. Blessing, J. Malfetano, 1990, American journal of clinical oncology.

Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.

T. Whelan, M. Brundage, J. Ingle, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Emergency department visits and hospitalizations in older women treated for early stage breast cancer.

A. Deal, H. Muss, Dillon C. Cockrell, 2023, Journal of geriatric oncology.

Cachexia in patients with cancer.

H. Muss, G. Williams, S. S. Shachar, 2016, The Lancet. Oncology.

ACCO: ASCO core curriculum outline.

J. V. Von Roenn, L. Deangelis, P. Harari, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dosage Range Study of Morphine Sulfate Controlled‐Release

H. Muss, H. Homesley, C. Welander, 1986, American journal of clinical oncology.

Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer.

H. Cohen, S. Mohile, A. Gajra, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nonseminomatous germ cell cancer of the testis. Reducing treatment‐related morbidity in patients with disseminated disease

C. Spurr, H. Muss, M. Cooper, 1982, Cancer.

Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer.

L. Carey, N. Sharpless, A. Deal, 2014, Journal of the National Cancer Institute.

Brain Scanning in Patients with Advanced Lung Cancer

H. Muss, D. White, R. J. Cowan, 1976 .

Fluoxymesterone as Third Line Endocrine Therapy for Advanced Breast Cancer A Phase II Trial of the Piedmont Oncology Association

H. Muss, P. Zekan, D. Jackson, 1992, American journal of clinical oncology.

Symptom management in metastatic breast cancer.

H. Muss, W. Irvin, D. Mayer, 2011, The oncologist.

Geriatric Assessment of Older Adults With Cancer During Unplanned Hospitalizations: An Opportunity in Disguise.

A. Bryant, H. Muss, G. Williams, 2015, The oncologist.

Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial.

H. Muss, W. Tew, H. Klepin, 2023, Cancer.

Myosteatosis and prognosis in cancer: Systematic review and meta-analysis.

H. Muss, G. Williams, S. Shachar, 2019, Critical reviews in oncology/hematology.

Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review

H. Muss, G. Williams, K. Nyrop, 2019, Breast Cancer Research and Treatment.

Research Methods: Translational Research in Geriatric Oncology

H. Muss, G. Williams, S. S. Shachar, 2020, Geriatric Oncology.

Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF)

C. Spurr, H. Muss, M. Cooper, 2004, Cancer Chemotherapy and Pharmacology.

Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors.

L. Carey, J. Frelinger, L. Bixby, 2023, Journal of immunology.

Breast Cancer in Older Women

G. Kimmick, H. Muss, 1995, Clinics in geriatric medicine.

Clinician perspectives on patient‐centered conversations about weight management with patients with early breast cancer

H. Muss, K. Nyrop, M. Charlot, 2023, Cancer.

Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer Survival

H. Muss, M. Lipsyc-Sharf, Ann H. Partridge, 2023, JAMA network open.

Determinants of black/white differences in colon cancer survival.

C. Redmond, R. Coates, C. Fenoglio-Preiser, 1995, Journal of the National Cancer Institute.

Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.

H. Joensuu, V. Nekljudova, T. Reimer, 2022, European journal of cancer.

Differences between black and white women with breast cancer in time from symptom recognition to medical consultation. Black/White Cancer Survival Study Group.

B. Hankey, R. Coates, B. Edwards, 1992, Journal of the National Cancer Institute.